Search Results
Sep 10, 2026, 10:45 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - REGN
the "Phase 3 Trial of Fianlimab . . . did not reach statistical significance for the primary endpoint of improvement in progression-free survival (PFS)." On this news, Regeneron's stock price fell $68.57 per share, or 9.82%, to close at $629.68 per share on May 16, 2026.Pomerantz LLP, with
More news about: Pomerantz LLP
Sep 10, 2026, 10:24 ET CordenPharma、無菌充填・包装能力を年間5億単位の無菌注射剤に拡大
Bausch & Ströbelが提供する、プレフィルドシリンジ（PFS）、バイアル、カートリッジ向けの臨床用および小規模商業用コンボライン。Syntegonの高速PFSおよびカートリッジ生産ラインで、1日あたり50万ユニット以上の生産が可能。PFS、バイアル、アンプル向けの自動二次包装エリアの拡張。拡大するプロジェクトパイプラインに対応するため、分析能力を倍増。新しいアイソレーターラインの完成は、それぞれ2027年半ばおよび2028年半ばを目標としており、これにより、CordenPharmaは無菌
More news about: CordenPharma
Sep 10, 2026, 10:15 ET CordenPharma porte sa capacité de remplissage et de conditionnement aseptiques à 500 millions d'unités injectables stériles par an
seringues préremplies (PFS), les flacons et les cartouches.Une ligne de production à grande vitesse de PFS et de cartouches de Syntegon, capable de produire plus de 500 000 unités par jour.L'agrandissement de la zone de conditionnement secondaire automatisé pour les PFS, les flacons et les
More news about: CordenPharma
Sep 10, 2026, 10:10 ET SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of September 14, 2026 in Regeneron Pharmaceuticals, Inc. Lawsuit - REGN
therapies.A protocol amendment expanded the PFS analysis population to include all patients with at least 6 months of follow-up.The study ultimately did not reach statistical significance for its primary endpoint of improved PFS.Alleged
More news about: SueWallSt.com
Sep 10, 2026, 09:58 ET 코든파마, 무균 충전•마감 생산능력 연간 5억 개 멸균 주사제 단위로 확대
바우쉬 앤드 스트뢰벨(Bausch & Ströbel)의 사전충전형 주사기(PFS), 바이알 및 카트리지용 임상•소규모 상업생산 겸용 라인하루 50만 개를 초과해 생산할 수 있는 신테곤(Syntegon)의 고속 PFS 및 카트리지 라인PFS, 바이알 및 앰풀용 자동 2차 포장 구역 확대증가하는 프로젝트 파이프라인을 지원하기 위한 분석 역량 2배 확대신규 아이솔레이터 라인의 완공은 각각 2027년 중반과 2028년을 목표로 하고 있으며, 이를 통해
More news about: CordenPharma
Sep 10, 2026, 08:45 ET Mines Do Not Usually Fail on Geology. They Stall on Land Access
completed documentation. Expanding the programme scope increases the amount payable. Separately, Imwelo has been the subject of JORC-compliant PEA, PFS and updated PFS work, but those foreign-code studies are not current under NI 43-101; the Company has not completed a feasibility study establishing mineral
More news about: Equity Insider
Sep 10, 2026, 07:00 ET LAKE VICTORIA GOLD ADVANCES IMWELO PHASE 3 LAND PROGRAMME TOWARD FINAL APPROVAL AND COMPENSATION
stage of development.Cautionary Note on Production DecisionAlthough Imwelo has been the subject of JORC-compliant PEA, PFS and updated PFS work, these foreign-code studies are not current under NI 43-101. The Company has not completed a feasibility study on Imwelo that establishes
More news about: Lake Victoria Gold Ltd.
Sep 10, 2026, 07:00 ET BioLineRx and Hemispherian AS to Present Encouraging GLIX1 Preclinical Efficacy Data and its Phase 1/2a Trial Design at the 21st Meeting of the European Association of Neuro-Oncology (EANO 2026)
glioma (≤2 prior therapy lines). Primary endpoints are safety, tolerability, and MTD/RP2D; secondary endpoints include PK, antitumor response, 6-month PFS, and exploratory endpoints include pharmacodynamic markers (P21, TMEM71, 5hmC, 5mC, γH2AX). Four leading US academic institutions will enroll patients
More news about: BioLineRx Ltd.; Hemispherian AS
Sep 10, 2026, 05:43 ET CordenPharma aumenta su capacidad de llenado y acabado aséptico a 500 millones de unidades inyectables
para uso clínico como para producción comercial a pequeña escala, destinada a jeringas precargadas (PFS), viales y cartuchos.• Una línea de alta velocidad de Syntegon para jeringas precargadas (PFS) y cartuchos, con capacidad para producir más de 500.000 unidades al día.• Ampliación del
More news about: CordenPharma
Sep 10, 2026, 03:26 ET /C O R R E C T I O N -- CordenPharma/
from Bausch & Ströbel for Pre-Filled Syringes (PFS), vials, and cartridges.A high-speed PFS & cartridge line from Syntegon, capable of producing >500,000 units per day.Expansion of the automatic secondary packaging area for PFS, vials, and ampoules.A doubling of analytical
More news about: CordenPharma
Sep 10, 2026, 02:48 ET /C O R R E C T I O N -- CordenPharma/
from Bausch & Ströbel for Pre-Filled Syringes (PFS), vials, and cartridges.A high-speed PFS & cartridge line from Syntegon, capable of producing >500,000 units per day.Expansion of the automatic secondary packaging area for PFS, vials, and ampoules.A doubling of analytical
More news about: CordenPharma
Sep 09, 2026, 20:15 ET REGN MONDAY DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit
the "Phase 3 Trial of Fianlimab . . . did not reach statistical significance for the primary endpoint of improvement in progression-free survival (PFS)." On this news, the price of Regeneron stock dropped nearly 10%, according to the complaint.THE LEAD PLAINTIFF PROCESS: The Private Securities
More news about: Robbins Geller Rudman & Dowd LLP
Sep 09, 2026, 16:59 ET REGN ALERT: Hagens Berman Alerts Regeneron Pharmaceuticals, Inc. (REGN) Investors to Pending Securities Fraud Class Action Amid Disclosures About Key Trial's Protocol and Ultimate Failure
Study's primary endpoint was progression-free survival ("PFS") and Regeneron has characterized the combination as a "potential blockbuster." "Events" – disease progression or death – determined the timing and statistical power of the primary PFS analysis.The complaint alleges that
More news about: Hagens Berman Sobol Shapiro LLP
Sep 08, 2026, 14:03 ET Global Antimony Market Projected to Reach $4.5 Billion by 2036, But the Binding Constraint Is the Permitting Clock
pre-feasibility study required for the Fast-Track mining application.Substantive Fast-Track application targeted for October 2026, with the PFS to be published in December 2026.RUA GOLD Inc. (OTCQX:
More news about: American News Group
Sep 08, 2026, 09:00 ET IMDELLTRA® IN COMBINATION WITH IMFINZI® DEMONSTRATED LANDMARK IMPROVEMENT IN OVERALL SURVIVAL IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER
chemotherapy and etoposide. The study also demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) and objective response rate (ORR) among patients treated with IMDELLTRA in combination with durvalumab.Overall, the safety profile of IMDELLTRA
More news about: Amgen
Sep 08, 2026, 07:30 ET Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC Study
responses in the control arm. Median progression-free survival (PFS) continues to mature. As of the data cutoff, median PFS was 9.6 months for INBRX-106 plus pembrolizumab compared with 4.9 months for pembrolizumab alone, with six-month PFS rates of 72.4% and 42.8%, respectively.The efficacy signal
More news about: Inhibrx Biosciences, Inc.
Sep 08, 2026, 07:00 ET Thick, High-Grade, Surface Enrichment Zone Extends at La Verde
Study (PFS) IntegrationHot Chili continues to advance resource definition and development workstreams at La Verde, with a maiden Mineral Resource Estimate (MRE) targeted for completion later this year. The Company expects to follow with a revised Costa Fuego Pre-Feasibility Study (PFS), incorporating
More news about: Hot Chili Limited
Sep 08, 2026, 06:30 ET MAYFAIR GOLD ADVANCES EXPLORATION TARGETS AND PROJECT GEOLOGY AT FENN-GIB
(the "PFS")1 is to develop the project under the provincial permitting process, targeting the higher-grade 1 million ounce probable mineral reserve (25.1Mt at an average grade of 1.29g/t) sitting near-surface, highlighting the optionality and scalability provided by the deposit. The PFS also
More news about: Mayfair Gold Corp.
Sep 08, 2026, 05:00 ET Canadian Energy Metals erbringt den Proof-of-Concept für Aluminiumoxid in Schmelzqualität aus einer nicht-Bauxit-Ressource und beginnt mit der Vor-Machbarkeitsstudie
wird – dem derzeitigen Industriestandard.Darüber hinaus bestätigt das Unternehmen den offiziellen Beginn seiner Vor-Machbarkeitsstudie („PFS"). Eine PFS liefert eine fundierte technische und wirtschaftliche Bewertung, die die Abbau-, Aufbereitungs- und Verhüttungsprozesse von CEM definiert, die
More news about: Canadian Energy Metals Corp.
Sep 08, 2026, 05:00 ET Canadian Energy Metals Achieves Proof-of-Concept for Smelter Grade Alumina from a Non-Bauxite Resource & Commences its Prefeasibility Study
of refining bauxite, the current industry standard.In addition, the Company confirms the formal commencement of its Prefeasibility Study ("PFS"). A PFS provides a defensible engineering and economic assessment that defines CEM's mining, refining, and smelting pathways; upgrades resource confidence;
More news about: Canadian Energy Metals Corp.
Sep 08, 2026, 05:00 ET Canadian Energy Metals Achieves Proof-of-Concept for Smelter Grade Alumina from a Non-Bauxite Resource & Commences its Prefeasibility Study
of refining bauxite, the current industry standard.In addition, the Company confirms the formal commencement of its Prefeasibility Study ("PFS"). A PFS provides a defensible engineering and economic assessment that defines CEM's mining, refining, and smelting pathways; upgrades resource confidence;
More news about: Canadian Energy Metals Corp.
Sep 08, 2026, 05:00 ET Canadian Energy Metals valide le concept de production d'alumine de qualité métallurgique à partir d'une ressource autre que la bauxite et lance son étude de préfaisabilité
constitue la norme industrielle actuelle.Par ailleurs, la Société confirme le lancement officiel de son étude de préfaisabilité (« PFS »). Une étude de pré-faisabilité (PFS) fournit une analyse technique et économique solide qui définit les filières d'exploitation minière, de raffinage et de fusion de
More news about: Canadian Energy Metals Corp.
Sep 07, 2026, 13:19 ET REGN 1-WEEK DEADLINE ALERT: Regeneron Pharmaceuticals, Inc. Investors Alerted to September 14, 2026 Lead Plaintiff Deadline in Class Action Lawsuit
Study's primary endpoint was progression-free survival ("PFS") and Regeneron has characterized the combination as a "potential blockbuster." "Events" – disease progression or death – determined the timing and statistical power of the primary PFS analysis.The complaint alleges that
More news about: Hagens Berman Sobol Shapiro LLP
Sep 03, 2026, 19:10 ET REGN INVESTOR ALERT: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead the Regeneron Class Action Lawsuit
the "Phase 3 Trial of Fianlimab . . . did not reach statistical significance for the primary endpoint of improvement in progression-free survival (PFS)." On this news, the price of Regeneron stock dropped nearly 10%, according to the complaint.THE LEAD PLAINTIFF PROCESS: The Private Securities
More news about: Robbins Geller Rudman & Dowd LLP
Sep 03, 2026, 15:15 ET REGN ALERT: Hagens Berman Alerts Regeneron Pharmaceuticals, Inc. (REGN) Investors to Pending Securities Fraud Class Action Amid Disclosures About Key Trial's Protocol and Ultimate Failure
Study's primary endpoint was progression-free survival ("PFS") and Regeneron has characterized the combination as a "potential blockbuster." "Events" – disease progression or death – determined the timing and statistical power of the primary PFS analysis.The complaint alleges that
More news about: Hagens Berman Sobol Shapiro LLP